11:01 AM EDT, 08/20/2025 (MT Newswires) -- IRhythm Technologies' ( IRTC ) Zio mobile cardiac telemetry or MCT serves as an upcoming catalyst for the company, potentially driving share gains in the MCT segment, BofA Securities said in a Wednesday note.

Zio MCT is expected to be launched in H2 2026, with its filing with the US Food and Drug Administration slated for Q3, said the investment firm. According to BofA Securities, the predecessor product Zio AT has already spurred market share gains this year, from three points in H1 and an estimated mid-teens by year-end.

"iRhythm is displacing the standard of care in ambulatory cardiac monitoring," BofA Securities said, noting that the company also has market expansion opportunity in the long-term continuous monitoring segment with its Zio system.

BofA Securities initiated coverage on iRhythm Technologies ( IRTC ) and tagged the company with a buy rating and $200 price target.

Price: 161.32, Change: +2.80, Percent Change: +1.77